Skip to main content

Advertisement

SpringerLink
Log in

Antiplatelet Strategies for Secondary Prevention of Stroke and TIA

  • Clinical Trials and Their Interpretations (JR Kizer, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Stroke is a major public health issue, and stroke recurrence accounts for a quarter of all events. Antiplatelet therapy has been extensively studied for secondary stroke prevention and is established as effective in this high-risk population. Several agents have been evaluated in this setting, both in isolation and combination. The most widely used antiplatelet medications are aspirin, clopidogrel, and aspirin plus extended-release dipyridamole. However, new agents and combinations continue to be evaluated. A detailed review of the evidence supporting various antiplatelet regimens for secondary stroke prevention is outlined with special focus on recent developments that may impact clinical management of patients with stroke or TIA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. [Internet]. Circulation. 2014; e28–e292. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24352519.

  2. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, et al. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke [Internet]. 1998;29:2491–500. doi:10.1161/01.STR.29.12.2491.

    Article  CAS  Google Scholar 

  3. Jorgensen H, Nakayama H, Reith J, Raaschou H, Olsen T. Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study. Neurology. 1997;48:891–5.

    Article  PubMed  CAS  Google Scholar 

  4. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke [Internet]. 2001;32:2735–40. doi:10.1161/hs1201.100209.

    Article  CAS  Google Scholar 

  5. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke [Internet]. 2001;32:2559–66. doi:10.1161/hs1101.098524.

    Article  CAS  Google Scholar 

  6. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet [Internet]. Elsevier Ltd; 2009;373:1849–60. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2715005&tool=pmcentrez&rendertype=abstract.

  7. Zheng ASY, Churilov L, Colley RE, Goh C, Davis SM, Yan B. Association of aspirin resistance with increased stroke severity and infarct size. JAMA Neurol. [Internet]. 2013;70:208–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23165316.

  8. Englyst NA, Horsfield G, Kwan J, Byrne CD. Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J Cereb Blood Flow Metab. [Internet]. 2008;28:1196–203. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18319729. Results suggesting the risk of true aspirin resistance are very low, but pseudoresistance related to variable absorption complicates enteric-coated formulations.

  9. Schwammenthal Y, Tsabari R, Shenkman B, Schwartz R, Matetzky S, Lubetsky a, et al. Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome. Cerebrovasc Dis. [Internet]. 2008;25:355–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18305387.

  10. Grosser T, Fries S, Lawson J a, Kapoor SC, Grant GR, FitzGerald G a. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation [Internet]. 2013;127:377–85. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3552520&tool=pmcentrez&rendertype=abstract.

  11. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet [Internet]. 1996;348:1413–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8937281.

  12. Hirata Y, Kataoka H, Shimura T, Mizushima T, Mizoshita T, Tanida S, et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol [Internet]. 2011;46:803–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21501103.

  13. Walker J, Robinson J, Stewart J, Jacob S. Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? Interact. Cardiovasc Thorac Surg [Internet]. 2007;6:519–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17669925.

  14. Sørensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol [Internet]. 2000;95:2218–24. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=32172&tool=pmcentrez&rendertype=abstract.

  15. Côté R, Zhang Y, Hart RG, McClure L a, Anderson DC, Talbert RL, et al. ASA failure: Does the combination ASA/clopidogrel confer better long-term vascular protection? Neurology [Internet]. 2014; Available from: http://www.ncbi.nlm.nih.gov/pubmed/24384643.

  16. Renda G, Zurro M, Malatesta G, Ruggieri B, De Caterina R. Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. Haematologica [Internet]. 2010;95:2095–101. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2995568&tool=pmcentrez&rendertype=abstract.

  17. Buch AN, Singh S, Roy P, Javaid A, Smith K a, George CE, et al. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol [Internet]. 2007;99:1518–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17531573.

  18. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest [Internet]. 2008;133:299S–339S. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18574269.

  19. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P. Aspirin resistance: position paper of the Working Group on Aspirin Resistance 2005;1309–11.

  20. Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive services task force. Ann Intern Med. 2007;146:365–75.

    Article  PubMed  Google Scholar 

  21. Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet [Internet]. Elsevier Ltd; 2010;376:1741–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20970847.

  22. Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet [Internet]. Elsevier Ltd; 2012;379:1602–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22440946.

  23. Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet [Internet]. Elsevier Ltd; 2012;379:1591–601. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22440947.

  24. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol [Internet]. Elsevier Ltd; 2012;13:518–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22440112.

  25. Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Thibult N, Touboul D, et al. “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke [Internet]. 1983;14:5–14. doi:10.1161/01.STR.14.1.5.

    Article  CAS  Google Scholar 

  26. Group TA-CCS. Persantine Aspirin Trial in cerebral ischemia. Stroke [Internet]. 1983;14:99–103. doi:10.1161/01.STR.14.1.99.

    Article  Google Scholar 

  27. Group TE. The European Stroke Prevention Study (ESPS): Principle end-points. Lancet. 1987;1351–4.

  28. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci [Internet]. 1996;143:1–13.

    Article  CAS  Google Scholar 

  29. Leonardi-Bee J, Bath PMW, Bousser M-G, Davalos A, Diener H-C, Guiraud-Chaumeil B, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke. 2005;36:162–8.

    Article  PubMed  CAS  Google Scholar 

  30. Von Maxen A, Wille H, Schoenhoefer PS. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;368:448–9.

    Article  Google Scholar 

  31. Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). 1996;348:1329–39.

  32. Sacco RL, Diener H-C, Yusuf S, Cotton D, Ounpuu S, Lawton W a, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med [Internet]. 2008;359:1238–51. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2772657&tool=pmcentrez&rendertype=abstract.

  33. Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation [Internet]. 2012;125:1276–87; discussion 1287. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22412089.

  34. Krishna V, Diamond GA, Kaul S. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven. Circulation [Internet]. 2012;125:1288–303; discussion 1303. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22412090.

  35. Gagne JJ, Bykov K, Niteesh K, Toomey TJ. Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis. 2013;5307:1–10.

  36. Bauer T, Bouman HJ, Werkum JW Van. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. 2011;1–18.

  37. Collet J-P, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med [Internet]. 2012;367:2100–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23121439.

  38. Diener H-C, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet [Internet]. 2004;364:331–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15276392.

  39. Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med [Internet]. 2006;354:1706–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16752345.

  40. Usman MHU, Notaro L a, Nagarakanti R, Brahin E, Dessain S, Gracely E, et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol [Internet]. Elsevier Inc.; 2009;103:1107–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19361598. Results suggest lacunar stroke patients do not derive additional benefit from dual antiplatelet therapy and treatment should continue to be driven primarily by antiplatelet monotherapy and aggressive blood pressure control.

  41. Lee M, Saver J, Hong K, Rao N, Wu Y, Ovbiagele B. Risk–benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke. Ann Intern Med. 2014;159:463–70.

    Article  Google Scholar 

  42. Amarenco P, Donnan G a. Should the MATCH results be extrapolated to all stroke patients and affect ongoing trials evaluating clopidogrel plus aspirin? Stroke [Internet]. 2004;35:2606–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15472090. Results of surprisingly low rates of recurrent stroke in patients with intracranial atherosclerosis undergoing aggressive medical management including short-term dual antiplatelet therapy provided compelling evidence for change in clinical management of these patients.

  43. Benavente OR, Hart RG, McClure L a, Szychowski JM, Coffey CS, Pearce L a. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med [Internet]. 2012;367:817–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22931315. Results from primarily Chinese population showing significant benefit of early, short-term dual antiplatelet therapy in high-risk TIA and minor stroke patients. Greater generalizability will be supported by ongoing studies if these results are replicated.

  44. Amarenco P, Davis S, Jones EF, Cohen A a, Heiss W-D, Kaste M, et al. Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke [Internet]. 2014;45:1248–57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24699050.

  45. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med [Internet]. 2011;365:993–1003. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3580611&tool=pmcentrez&rendertype=abstract.

  46. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med [Internet]. 2013;369:11–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23803136.

  47. Gotoh F, Tohgi H, Hirai S, Terashi a, Fukuuchi Y, Otomo E, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis [Internet]. 2000;9:147–57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24192020.

  48. Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol [Internet]. 2008;7:494–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18456558.

  49. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol [Internet]. Elsevier Ltd; 2010; 9:959–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20833591.

  50. Dinicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O’Keefe JH, Bangalore S, et al. Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. Am J Cardiol [Internet]. Elsevier Inc.; 2013;112:1230–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23827403.

  51. Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.

    Article  PubMed  CAS  Google Scholar 

  52. James SK, Storey RF, Khurmi NS, Husted S, Keltai M, Mahaffey KW, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation [Internet]. 2012;125:2914–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22572911.

  53. Group TSC. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991;338:1345–9.

    Article  Google Scholar 

  54. Group TDTTS. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325:1261–6.

    Article  Google Scholar 

  55. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med [Internet]. 2009;360:2066–78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19336502.

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Koto Ishida and Steven R. Messé declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Neurology, New York University, New York, NY, 10016, USA

    Koto Ishida

  2. Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, 19104, USA

    Steven R. Messé

Authors
  1. Koto Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven R. Messé
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koto Ishida.

Additional information

This article is part of the Topical Collection on Clinical Trials and Their Interpretations

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ishida, K., Messé, S.R. Antiplatelet Strategies for Secondary Prevention of Stroke and TIA. Curr Atheroscler Rep 16, 449 (2014). https://doi.org/10.1007/s11883-014-0449-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-014-0449-6

Keywords

Search

Navigation